LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound...
-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE)...
Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness...
LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and...
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor,...
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...
Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for...
Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The...
For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core...
Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy...